These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
957 related articles for article (PubMed ID: 32154925)
1. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925 [TBL] [Abstract][Full Text] [Related]
2. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709 [TBL] [Abstract][Full Text] [Related]
4. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation. Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616 [TBL] [Abstract][Full Text] [Related]
5. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501 [TBL] [Abstract][Full Text] [Related]
6. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
7. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908 [TBL] [Abstract][Full Text] [Related]
8. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
9. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094 [TBL] [Abstract][Full Text] [Related]
10. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450 [TBL] [Abstract][Full Text] [Related]
11. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987 [No Abstract] [Full Text] [Related]
12. Real-World Analysis of the Efficacy of Rebiopsy and Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335 [TBL] [Abstract][Full Text] [Related]
13. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. Wang S; Cang S; Liu D J Hematol Oncol; 2016 Apr; 9():34. PubMed ID: 27071706 [TBL] [Abstract][Full Text] [Related]
14. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257 [TBL] [Abstract][Full Text] [Related]
15. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
17. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib. Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986 [TBL] [Abstract][Full Text] [Related]
18. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916 [TBL] [Abstract][Full Text] [Related]
19. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
20. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]